{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,21]],"date-time":"2025-12-21T08:25:17Z","timestamp":1766305517209,"version":"3.32.0"},"reference-count":45,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,1,7]],"date-time":"2025-01-07T00:00:00Z","timestamp":1736208000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,1,7]],"date-time":"2025-01-07T00:00:00Z","timestamp":1736208000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/501100001734","name":"Copenhagen University","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100001734","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Cancer"],"DOI":"10.1186\/s12885-024-13369-1","type":"journal-article","created":{"date-parts":[[2025,1,7]],"date-time":"2025-01-07T13:27:28Z","timestamp":1736256448000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Molecularly redefining small bowel adenocarcinoma to accelerate precision patient care \u2013 protocol of a multicenter observational cohort biomarker study"],"prefix":"10.1186","volume":"25","author":[{"given":"Rasmus Haunstrup","family":"D\u00f8ssing","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Julia Johanna Almer","family":"Broman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Colm J.","family":"O\u2019Rourke","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Elizaveta Mitkina","family":"Tabaksblat","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jesper B\u00f8je","family":"Andersen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Carsten Paln\u00e6s","family":"Hansen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tim Svenstrup","family":"Poulsen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Estrid V. S.","family":"H\u00f8gdall","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jakob Hagen Vasehus","family":"Schou","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dan","family":"H\u00f8gdall","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,1,7]]},"reference":[{"key":"13369_CR1","doi-asserted-by":"publisher","first-page":"257","DOI":"10.1016\/j.clcc.2019.08.002","volume":"18","author":"M Akce","year":"2019","unstructured":"Akce M, Jiang R, Zakka K, Wu C, Alese OB, Shaib WL, et al. Clinical outcomes of small bowel adenocarcinoma. Clin Colorectal Cancer. 2019;18:257\u201368.","journal-title":"Clin Colorectal Cancer"},{"key":"13369_CR2","doi-asserted-by":"publisher","first-page":"725","DOI":"10.3109\/02841861003782017","volume":"49","author":"G Engholm","year":"2010","unstructured":"Engholm G, Ferlay J, Christensen N, Bray F, Gjerstorff ML, Klint \u00c5, et al. NORDCAN \u2013 a Nordic tool for cancer information, planning, quality control and research. Acta Oncol (Madr). 2010;49:725\u201336.","journal-title":"Acta Oncol (Madr)"},{"key":"13369_CR3","doi-asserted-by":"publisher","first-page":"17","DOI":"10.3322\/caac.21763","volume":"73","author":"RL Siegel","year":"2023","unstructured":"Siegel RL, Miller KD, Wagle NS, Jemal A. Cancer statistics, 2023. CA Cancer J Clin. 2023;73:17\u201348.","journal-title":"CA Cancer J Clin"},{"key":"13369_CR4","doi-asserted-by":"publisher","first-page":"534","DOI":"10.1038\/nrclinonc.2013.132","volume":"10","author":"K Raghav","year":"2013","unstructured":"Raghav K, Overman MJ. Small bowel adenocarcinomas\u2013existing evidence and evolving paradigms. Nat Rev Clin Oncol. 2013;10:534\u201344.","journal-title":"Nat Rev Clin Oncol"},{"key":"13369_CR5","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1016\/j.clcc.2021.11.006","volume":"21","author":"IS Yu","year":"2022","unstructured":"Yu IS, Al-Hashami Z, Chapani P, Speers C, Davies JM, Lim HJ, et al. Impact of tumor location on patient outcomes in small bowel cancers. Clin Colorectal Cancer. 2022;21:107\u201313.","journal-title":"Clin Colorectal Cancer"},{"key":"13369_CR6","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1097\/SLA.0b013e31818e4641","volume":"249","author":"KY Bilimoria","year":"2009","unstructured":"Bilimoria KY, Bentrem DJ, Wayne JD, Ko CY, Bennett CL, Talamonti MS. Small bowel cancer in the United States: changes in epidemiology, treatment, and survival over the last 20 years. Ann Surg. 2009;249:63\u201371.","journal-title":"Ann Surg"},{"key":"13369_CR7","doi-asserted-by":"publisher","first-page":"518","DOI":"10.1002\/cncr.20404","volume":"101","author":"BS Dabaja","year":"2004","unstructured":"Dabaja BS, Suki D, Pro B, Bonnen M, Ajani J. Adenocarcinoma of the small bowel. Cancer. 2004;101:518\u201326.","journal-title":"Cancer"},{"key":"13369_CR8","doi-asserted-by":"publisher","first-page":"220","DOI":"10.1016\/j.clcc.2016.08.002","volume":"16","author":"D Aydin","year":"2017","unstructured":"Aydin D, Sendur MA, Kefeli U, Unal OU, Tastekin D, Akyol M, et al. Evaluation of prognostic factors and adjuvant chemotherapy in patients with small bowel adenocarcinoma who underwent curative resection. Clin Colorectal Cancer. 2017;16:220\u20137.","journal-title":"Clin Colorectal Cancer"},{"key":"13369_CR9","doi-asserted-by":"publisher","first-page":"306","DOI":"10.1097\/DCR.0000000000000562","volume":"59","author":"JI Young","year":"2016","unstructured":"Young JI, Mongoue-Tchokote S, Wieghard N, Mori M, Vaccaro GM, Sheppard BC, et al. Treatment and survival of small-bowel adenocarcinoma in the United States: a comparison with colon cancer. Dis Colon Rectum. 2016;59:306\u201315.","journal-title":"Dis Colon Rectum"},{"key":"13369_CR10","doi-asserted-by":"publisher","first-page":"905","DOI":"10.1007\/s10147-017-1138-6","volume":"22","author":"T Horimatsu","year":"2017","unstructured":"Horimatsu T, Nakayama N, Moriwaki T, Hirashima Y, Fujita M, Asayama M, et al. A phase II study of 5-fluorouracil\/L-leucovorin\/oxaliplatin (mFOLFOX6) in Japanese patients with metastatic or unresectable small bowel adenocarcinoma. Int J Clin Oncol. 2017;22:905\u201312.","journal-title":"Int J Clin Oncol"},{"key":"13369_CR11","doi-asserted-by":"publisher","first-page":"561","DOI":"10.1097\/CAD.0b013e328350dd0d","volume":"23","author":"XJ Xiang","year":"2012","unstructured":"Xiang XJ, Liu YW, Zhang L, Qiu F, Yu F, Zhan ZY, et al. A phase II study of modified FOLFOX as first-line chemotherapy in advanced small bowel adenocarcinoma. Anticancer Drugs. 2012;23:561\u20136.","journal-title":"Anticancer Drugs"},{"key":"13369_CR12","doi-asserted-by":"publisher","first-page":"1422","DOI":"10.1002\/cncr.25614","volume":"117","author":"A Zaanan","year":"2011","unstructured":"Zaanan A, Gauthier M, Malka D, Locher C, Gornet JM, Thirot-Bidault A, et al. Second-line chemotherapy with fluorouracil, leucovorin, and irinotecan (FOLFIRI regimen) in patients with advanced small bowel adenocarcinoma after failure of first-line platinum-based chemotherapy: a multicenter AGEO study. Cancer. 2011;117:1422\u20138.","journal-title":"Cancer"},{"key":"13369_CR13","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1016\/j.clcc.2019.01.005","volume":"18","author":"AI Neugut","year":"2019","unstructured":"Neugut AI, Lin A, Raab GT, Hillyer GC, Keller D, O\u2019Neil DS, et al. FOLFOX and FOLFIRI use in stage IV colon cancer: analysis of SEER-medicare data. Clin Colorectal Cancer. 2019;18:133\u201340.","journal-title":"Clin Colorectal Cancer"},{"key":"13369_CR14","doi-asserted-by":"publisher","first-page":"20863","DOI":"10.18632\/oncotarget.4576","volume":"6","author":"MA Alvi","year":"2015","unstructured":"Alvi MA, McArt DG, Kelly P, Fuchs MA, Alderdice M, McCabe CM, et al. Comprehensive molecular pathology analysis of small bowel adenocarcinoma reveals novel targets with potential for clinical utility. Oncotarget. 2015;6:20863\u201374.","journal-title":"Oncotarget"},{"key":"13369_CR15","doi-asserted-by":"publisher","first-page":"367","DOI":"10.1093\/annonc\/mdr122","volume":"23","author":"JC Haan","year":"2012","unstructured":"Haan JC, Buffart TE, Eijk PP, van de Wiel MA, van Wieringen WN, Howdle PD, et al. Small bowel adenocarcinoma copy number profiles are more closely related to colorectal than to gastric cancers. Ann Oncol. 2012;23:367\u201374.","journal-title":"Ann Oncol"},{"key":"13369_CR16","doi-asserted-by":"publisher","first-page":"11491","DOI":"10.1002\/cam4.5877","volume":"12","author":"M Nakamura","year":"2023","unstructured":"Nakamura M, Okamura Y, Ohshima K, Sugiura T, Ashida R, Ohgi K, et al. Molecular genetic positioning of small intestine and papilla of Vater carcinomas including clinicopathological classification. Cancer Med. 2023;12:11491\u2013502.","journal-title":"Cancer Med"},{"key":"13369_CR17","doi-asserted-by":"publisher","first-page":"4018","DOI":"10.1200\/JCO.2022.40.16_suppl.4018","volume":"40 16_suppl:","author":"K Pandya","year":"2022","unstructured":"Pandya K, Xiu J, Farrell A, Overman MJ, Seeber A, Abraham J, et al. Comprehensive genomic and transcriptomic characterization of small bowel adenocarcinoma. J Clin Oncol. 2022;40 16_suppl:4018\u20134018.","journal-title":"J Clin Oncol"},{"key":"13369_CR18","doi-asserted-by":"publisher","first-page":"2018","DOI":"10.3390\/cancers12082018","volume":"12","author":"E-V Wirta","year":"2020","unstructured":"Wirta E-V, Szeto S, H\u00e4nninen U, Ahtiainen M, B\u00f6hm J, Mecklin J-P, et al. Prognostic value of immune environment analysis in small bowel adenocarcinomas with verified mutational landscape and predisposing conditions. Cancers (Basel). 2020;12:2018.","journal-title":"Cancers (Basel)"},{"key":"13369_CR19","doi-asserted-by":"publisher","first-page":"1546","DOI":"10.1001\/jamaoncol.2017.1051","volume":"3","author":"AB Schrock","year":"2017","unstructured":"Schrock AB, Devoe CE, McWilliams R, Sun J, Aparicio T, Stephens PJ, et al. Genomic profiling of small-bowel adenocarcinoma. JAMA Oncol. 2017;3:1546.","journal-title":"JAMA Oncol"},{"key":"13369_CR20","doi-asserted-by":"publisher","first-page":"1429","DOI":"10.1158\/1078-0432.CCR-20-2892","volume":"27","author":"A Latham","year":"2021","unstructured":"Latham A, Shia J, Patel Z, Reidy-Lagunes DL, Segal NH, Yaeger R, et al. Characterization and clinical outcomes of DNA mismatch repair-deficient small bowel adenocarcinoma. Clin Cancer Res. 2021;27:1429\u201337.","journal-title":"Clin Cancer Res"},{"key":"13369_CR21","doi-asserted-by":"crossref","unstructured":"Vitiello F, Cereda S, Foti S, Liscia N, Mazza E, Ronzoni M, et al. Immunotherapy in small bowel adenocarcinoma: a potential role? Immunol Med.\u00a02024;47(1):1\u20135.","DOI":"10.1080\/25785826.2023.2220938"},{"key":"13369_CR22","doi-asserted-by":"publisher","first-page":"3641","DOI":"10.1158\/1078-0432.CCR-21-0159","volume":"27","author":"KS Pedersen","year":"2021","unstructured":"Pedersen KS, Foster NR, Overman MJ, Boland PM, Kim SS, Arrambide KA, et al. ZEBRA: a multicenter phase II study of pembrolizumab in patients with advanced small-bowel adenocarcinoma. Clin Cancer Res. 2021;27:3641\u20138.","journal-title":"Clin Cancer Res"},{"key":"13369_CR23","doi-asserted-by":"publisher","first-page":"e70","DOI":"10.1016\/S1470-2045(15)00396-4","volume":"17","author":"L Billingham","year":"2016","unstructured":"Billingham L, Malottki K, Steven N. Research methods to change clinical practice for patients with rare cancers. Lancet Oncol. 2016;17:e70-80.","journal-title":"Lancet Oncol"},{"key":"13369_CR24","doi-asserted-by":"publisher","first-page":"300","DOI":"10.1093\/annonc\/mdu459","volume":"26","author":"PG Casali","year":"2015","unstructured":"Casali PG, Bruzzi P, Bogaerts J, Rare Cancers Europe (RCE) Consensus Panel. Rare Cancers Europe (RCE) methodological recommendations for clinical studies in rare cancers: a European consensus position paper. Ann Oncol. 2015;26:300\u20136.","journal-title":"Ann Oncol"},{"key":"13369_CR25","doi-asserted-by":"publisher","first-page":"1634","DOI":"10.1158\/2159-8290.CD-21-0612","volume":"12","author":"LJ Schipper","year":"2022","unstructured":"Schipper LJ, Zeverijn LJ, Garnett MJ, Voest EE. Can drug repurposing accelerate precision oncology? Cancer Discov. 2022;12:1634\u201341.","journal-title":"Cancer Discov"},{"key":"13369_CR26","doi-asserted-by":"publisher","first-page":"1402","DOI":"10.1158\/1078-0432.CCR-21-3752","volume":"28","author":"LR Hoes","year":"2022","unstructured":"Hoes LR, van Berge Henegouwen JM, van der Wijngaart H, Zeverijn LJ, van der Velden DL, van de Haar J, et al. Patients with Rare Cancers in the Drug Rediscovery Protocol (DRUP) benefit from genomics-guided treatment. Clin Cancer Res. 2022;28:1402\u201311.","journal-title":"Clin Cancer Res"},{"key":"13369_CR27","doi-asserted-by":"publisher","first-page":"1350","DOI":"10.1038\/nm.3967","volume":"21","author":"J Guinney","year":"2015","unstructured":"Guinney J, Dienstmann R, Wang X, de Reyni\u00e8s A, Schlicker A, Soneson C, et al. The consensus molecular subtypes of colorectal cancer. Nat Med. 2015;21:1350\u20136.","journal-title":"Nat Med"},{"key":"13369_CR28","doi-asserted-by":"publisher","unstructured":"Martin-Serrano MA, Kepecs B, Torres-Martin M, Bramel ER, Haber PK, Merritt E, et al. Novel microenvironment-based classification of intrahepatic cholangiocarcinoma with therapeutic implications. Gut. 2022. https:\/\/doi.org\/10.1136\/GUTJNL-2021-326514.","DOI":"10.1136\/GUTJNL-2021-326514"},{"key":"13369_CR29","doi-asserted-by":"publisher","first-page":"e1001216","DOI":"10.1371\/journal.pmed.1001216","volume":"9","author":"DG Altman","year":"2012","unstructured":"Altman DG, McShane LM, Sauerbrei W, Taube SE. Reporting recommendations for Tumor Marker Prognostic Studies (REMARK): explanation and elaboration. PLoS Med. 2012;9:e1001216.","journal-title":"PLoS Med"},{"key":"13369_CR30","doi-asserted-by":"publisher","first-page":"1180","DOI":"10.1093\/jnci\/dji237","volume":"97","author":"LM McShane","year":"2005","unstructured":"McShane LM, Altman DG, Sauerbrei W, Taube SE, Gion M, Clark GM, et al. Reporting Recommendations for Tumor Marker Prognostic Studies (REMARK). J Natl Cancer Inst. 2005;97:1180\u20134.","journal-title":"J Natl Cancer Inst"},{"key":"13369_CR31","doi-asserted-by":"publisher","first-page":"112","DOI":"10.1016\/j.jclinepi.2014.11.010","volume":"68","author":"GS Collins","year":"2015","unstructured":"Collins GS, Reitsma JB, Altman DG, Moons KGM. Transparent Reporting of a Multivariable Prediction Model for Individual Prognosis Or Diagnosis (TRIPOD): the TRIPOD statement. J Clin Epidemiol. 2015;68:112\u201321.","journal-title":"J Clin Epidemiol"},{"key":"13369_CR32","doi-asserted-by":"publisher","first-page":"1113","DOI":"10.1038\/ng.2764","volume":"45","author":"JN Weinstein","year":"2013","unstructured":"Weinstein JN, Collisson EA, Mills GB, Shaw KRM, Ozenberger BA, Ellrott K, et al. The cancer Genome Atlas Pan-Cancer analysis project. Nat Genet. 2013;45:1113\u201320.","journal-title":"Nat Genet"},{"key":"13369_CR33","doi-asserted-by":"publisher","first-page":"4011","DOI":"10.1200\/JCO.2021.39.15_suppl.4011","volume":"39 15_suppl","author":"S Perera","year":"2021","unstructured":"Perera S, Jang GH, Zhang A, Denroche RE, Dodd A, Ramotar S, et al. hENT1 gene expression as a predictor of response to gemcitabine and nab-paclitaxel in advanced pancreatic cancer. J Clin Oncol. 2021;39 15_suppl:4011\u20134011.","journal-title":"J Clin Oncol"},{"key":"13369_CR34","doi-asserted-by":"publisher","first-page":"398","DOI":"10.1016\/S1470-2045(19)30798-3","volume":"21","author":"JA Bridgewater","year":"2020","unstructured":"Bridgewater JA, Pugh SA, Maishman T, Eminton Z, Mellor J, Whitehead A, et al. Systemic chemotherapy with or without cetuximab in patients with resectable colorectal liver metastasis (New EPOC): long-term results of a multicentre, randomised, controlled, phase 3 trial. Lancet Oncol. 2020;21:398\u2013411.","journal-title":"Lancet Oncol"},{"key":"13369_CR35","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1016\/S0140-6736(07)61087-3","volume":"370","author":"MT Seymour","year":"2007","unstructured":"Seymour MT, Maughan TS, Ledermann JA, Topham C, James R, Gwyther SJ, et al. Different strategies of sequential and combination chemotherapy for patients with poor prognosis advanced colorectal cancer (MRC FOCUS): a randomised controlled trial. Lancet. 2007;370:143\u201352.","journal-title":"Lancet"},{"key":"13369_CR36","doi-asserted-by":"publisher","first-page":"1895","DOI":"10.1093\/annonc\/mdy263","volume":"29","author":"J Mateo","year":"2018","unstructured":"Mateo J, Chakravarty D, Dienstmann R, Jezdic S, Gonzalez-Perez A, Lopez-Bigas N, et al. A framework to rank genomic alterations as targets for cancer precision medicine: the ESMO Scale for Clinical Actionability of molecular Targets (ESCAT). Ann Oncol. 2018;29:1895\u2013902.","journal-title":"Ann Oncol"},{"key":"13369_CR37","doi-asserted-by":"publisher","first-page":"1022","DOI":"10.1016\/S1470-2045(17)30445-X","volume":"18","author":"G Gatta","year":"2017","unstructured":"Gatta G, Capocaccia R, Botta L, Mallone S, De Angelis R, Ardanaz E, et al. Burden and centralised treatment in Europe of rare tumours: results of RARECAREnet-a population-based study. Lancet Oncol. 2017;18:1022\u201339.","journal-title":"Lancet Oncol"},{"key":"13369_CR38","doi-asserted-by":"publisher","first-page":"100174","DOI":"10.1016\/j.esmoop.2021.100174","volume":"6","author":"J-Y Blay","year":"2021","unstructured":"Blay J-Y, Casali P, Bouvier C, Dehais C, Galloway I, Gietema J, et al. European Reference Network for rare adult solid cancers, statement and integration to health care systems of member states: a position paper of the ERN EURACAN. ESMO Open. 2021;6:100174.","journal-title":"ESMO Open"},{"key":"13369_CR39","doi-asserted-by":"publisher","first-page":"554","DOI":"10.1016\/j.molmed.2023.03.007","volume":"29","author":"D Ostroverkhova","year":"2023","unstructured":"Ostroverkhova D, Przytycka TM, Panchenko AR. Cancer driver mutations: predictions and reality. Trends Mol Med. 2023;29:554\u201366.","journal-title":"Trends Mol Med"},{"key":"13369_CR40","doi-asserted-by":"publisher","first-page":"e79895","DOI":"10.7554\/eLife.79895","volume":"11","author":"S Mansouri","year":"2022","unstructured":"Mansouri S, Heylmann D, Stiewe T, Kracht M, Savai R. Cancer genome and tumor microenvironment: Reciprocal crosstalk shapes lung cancer plasticity. Elife. 2022;11:e79895.","journal-title":"Elife"},{"key":"13369_CR41","doi-asserted-by":"publisher","first-page":"389","DOI":"10.1038\/s41586-022-04735-9","volume":"606","author":"M \u0141uksza","year":"2022","unstructured":"\u0141uksza M, Sethna ZM, Rojas LA, Lihm J, Bravi B, Elhanati Y, et al. Neoantigen quality predicts immunoediting in survivors of pancreatic cancer. Nature. 2022;606:389\u201395.","journal-title":"Nature"},{"key":"13369_CR42","doi-asserted-by":"publisher","first-page":"eabq5089","DOI":"10.1126\/sciadv.abq5089","volume":"8","author":"J-W Sidhom","year":"2022","unstructured":"Sidhom J-W, Oliveira G, Ross-MacDonald P, Wind-Rotolo M, Wu CJ, Pardoll DM, et al. Deep learning reveals predictive sequence concepts within immune repertoires to immunotherapy. Sci Adv. 2022;8:eabq5089.","journal-title":"Sci Adv"},{"key":"13369_CR43","doi-asserted-by":"publisher","first-page":"e81952","DOI":"10.7554\/eLife.81952","volume":"11","author":"M Pan","year":"2022","unstructured":"Pan M, Li B. T cell receptor convergence is an indicator of antigen-specific T cell response in cancer immunotherapies. Elife. 2022;11:e81952.","journal-title":"Elife"},{"key":"13369_CR44","doi-asserted-by":"publisher","first-page":"609","DOI":"10.1016\/j.ccell.2022.05.005","volume":"40","author":"DM Wolf","year":"2022","unstructured":"Wolf DM, Yau C, Wulfkuhle J, Brown-Swigart L, Gallagher RI, Lee PRE, et al. Redefining breast cancer subtypes to guide treatment prioritization and maximize response: predictive biomarkers across 10 cancer therapies. Cancer Cell. 2022;40:609-623.e6.","journal-title":"Cancer Cell"},{"key":"13369_CR45","doi-asserted-by":"publisher","unstructured":"Nepal C, O\u2019Rourke CJ, Oliveira DV, Taranta A, Shema S, Gautam P, et al. Genomic perturbations reveal distinct regulatory networks in intrahepatic cholangiocarcinoma. Hepatology. 2017. https:\/\/doi.org\/10.1002\/hep.29764.","DOI":"10.1002\/hep.29764"}],"container-title":["BMC Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-024-13369-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12885-024-13369-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-024-13369-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,1,8]],"date-time":"2025-01-08T02:03:13Z","timestamp":1736301793000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmccancer.biomedcentral.com\/articles\/10.1186\/s12885-024-13369-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,1,7]]},"references-count":45,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["13369"],"URL":"https:\/\/doi.org\/10.1186\/s12885-024-13369-1","relation":{},"ISSN":["1471-2407"],"issn-type":[{"type":"electronic","value":"1471-2407"}],"subject":[],"published":{"date-parts":[[2025,1,7]]},"assertion":[{"value":"2 February 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 December 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 January 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study is approved by the Danish National Ethics Committee as of 23rd October 2023 (case number: 2312342). Signed informed consent will be required from all prospectively included patients. The study has received dispensation from signed informed consent to include patients treated at the participating departments from 1st January 2010.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"22"}}